ImmunoCellular Therapeutics Ltd (IMUC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ImmunoCellular Therapeutics Ltd (IMUC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10026
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product pipeline comprises ICT-107, ICT-140 and ICT-121. ICT-107, the lead product candidate of the company is being developed for the treatment of glioblastoma multiforme (GBM); ICT-140, a DC vaccine designed to treat recurrent ovarian cancer; and ICT-121 for the treatment of recurrent GBM and other solid tumors. The company also develops stem cell therapies for treating cancer. As of March 2015, the development of ICT-140 has been put on hold. IMCU is headquartered in Calabasas, California, the US.

ImmunoCellular Therapeutics Ltd (IMUC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
ImmunoCellular Therapeutics to Enter into Agreement with Memgen 13
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 14
ImmunoCellular Therapeutics Enters into Research Agreement with University of Maryland, Baltimore 15
ImmunoCellular Therapeutics Enters into Agreement with Canadian Brain Tumour Consortium 16
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 17
ImmunoCellular Therapeutics Enters into Agreement with Pure MHC 18
Licensing Agreements 19
ImmunoCellular Therapeutics Enters into Licensing Agreement with California Institute of Technology 19
ImmunoCellular Enters Into Licensing Agreement With University of Pittsburgh 20
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 21
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 22
Equity Offering 23
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 23
ImmunoCellular Therapeutics Files for Rights Offering 25
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 26
ImmunoCellular Plans to Raise Funds through Public Offering of Shares 28
ImmunoCellular Therapeutics Raises USD16 Million in Public Offering of Shares and Warrants 29
ImmunoCellular Therapeutics Decreases Size Of Public Offering Of Shares For US$17 Million 30
ImmunoCellular Therapeutics Completes Public Offering Of Shares For US$21 Million 31
ImmunoCellular Therapeutics Completes Public Offering Of Units For US$10.4 Million 33
ImmunoCellular Therapeutics Ltd – Key Competitors 34
ImmunoCellular Therapeutics Ltd – Key Employees 35
ImmunoCellular Therapeutics Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 36
Recent Developments 37
Financial Announcements 37
Aug 13, 2018: ImmunoCellular Therapeutics provides corporate update and reports second quarter 2018 financial results 37
May 14, 2018: ImmunoCellular Therapeutics Reports First Quarter 2018 Financial Results 39
Mar 13, 2018: ImmunoCellular Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results 40
Nov 21, 2017: ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results 41
Aug 14, 2017: ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results 42
May 15, 2017: ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results 43
Mar 09, 2017: ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 44
Product News 46
12/13/2017: ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program 46
Apr 12, 2018: ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program 47
Other Significant Developments 48
Feb 13, 2018: ImmunoCellular Therapeutics Announces Update on Financial Condition 48
Aug 23, 2017: ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoCellular Therapeutics to Enter into Agreement with Memgen 13
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 14
ImmunoCellular Therapeutics Enters into Research Agreement with University of Maryland, Baltimore 15
ImmunoCellular Therapeutics Enters into Agreement with Canadian Brain Tumour Consortium 16
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 17
ImmunoCellular Therapeutics Enters into Agreement with Pure MHC 18
ImmunoCellular Therapeutics Enters into Licensing Agreement with California Institute of Technology 19
ImmunoCellular Enters Into Licensing Agreement With University of Pittsburgh 20
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 21
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 22
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 23
ImmunoCellular Therapeutics Files for Rights Offering 25
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 26
ImmunoCellular Plans to Raise Funds through Public Offering of Shares 28
ImmunoCellular Therapeutics Raises USD16 Million in Public Offering of Shares and Warrants 29
ImmunoCellular Therapeutics Decreases Size Of Public Offering Of Shares For US$17 Million 30
ImmunoCellular Therapeutics Completes Public Offering Of Shares For US$21 Million 31
ImmunoCellular Therapeutics Completes Public Offering Of Units For US$10.4 Million 33
ImmunoCellular Therapeutics Ltd, Key Competitors 34
ImmunoCellular Therapeutics Ltd, Key Employees 35
ImmunoCellular Therapeutics Ltd, Subsidiaries 36
ImmunoCellular Therapeutics Ltd, Joint Venture 36

List of Figures
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ImmunoCellular Therapeutics Ltd (IMUC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sanochemia Pharmazeutika AG (SAC)-医療機器分野:企業M&A・提携分析
    Summary Sanochemia Pharmazeutika AG (Sanochemia) is a specialty pharmaceutical company that develops and manufactures of innovative drugs in selected indication areas such as neurodegeneration, pain and cancer, as well as diagnostic products based on contrast media. The company’s product portfolio i …
  • Einstein Noah Restaurant Group, Inc. (Foodservice):企業の戦略・SWOT・財務情報
    Einstein Noah Restaurant Group, Inc. (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Einstein Noah Restaurant Group, Inc. (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • QDVC Q.S.C:企業の戦略的SWOT分析
    QDVC Q.S.C - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • The Hokuetsu Bank, Ltd.:企業の戦略・SWOT・財務情報
    The Hokuetsu Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Hokuetsu Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BAB, Inc.:企業の戦略・SWOT・財務情報
    BAB, Inc. - Strategy, SWOT and Corporate Finance Report Summary BAB, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Incyte Corp (INCY):企業の財務・戦略的SWOT分析
    Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Prominence Energy NL (SUR):企業の財務・戦略的SWOT分析
    Summary Prominence Energy NL(Prominence Energy) formerly known as Sun Resources NL is an oil and gas exploration and development company. The company explores and develops crude oil and natural gas. Its services include exploration, production, and development of unconventional oil and gas resources …
  • Okamoto Industries, Inc.
    Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Axela Inc-製薬・医療分野:企業M&A・提携分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …
  • Korea Electric Power Corporation (015760):企業の財務・戦略的SWOT分析
    Korea Electric Power Corporation (015760) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Delaware Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Delaware Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Teva Pharmaceutical Industries Ltd (TEVA):医療機器:M&Aディール及び事業提携情報
    Summary Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, cancer, …
  • UbiVac LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary UbiVac LLC (UbiVac) is a clinical stage immuno-oncology companythat offers immunotherapeutic products. The company offers research and development of therapeutic vaccines for the treatment of cancer and infectious diseases. Its pipeline product includes DPV-001, a DC-targeted complex vaccine …
  • Advaxis Inc (ADXS):企業の財務・戦略的SWOT分析
    Advaxis Inc (ADXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Piraeus Bank SA:企業のM&A・事業提携・投資動向
    Piraeus Bank SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Piraeus Bank SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Nishimatsu Construction Co Ltd (1820):企業の財務・戦略的SWOT分析
    Nishimatsu Construction Co Ltd (1820) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • BioFactura Inc-製薬・医療分野:企業M&A・提携分析
    Summary BioFactura Inc (Biofactura) is a biosimilars manufacturer that discovers, develops and markets biodefense drugs and client selected novel drugs. The company offers contract services such as process development, stable cell lines, and manufacturing. Its stable cell lines offers stable mammali …
  • Ascent Resources plc (AST):企業の財務・戦略的SWOT分析
    Ascent Resources plc (AST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • AS Kevelt-製薬・医療分野:企業M&A・提携分析
    Summary AS Kevelt (Kevelt), a subsidiary of Pharmsynthez is a healthcare company that develops, manufactures and markets drug products. The company offers products which include concentrate solutions for infusion, endocervical gel, eye drops and other solutions. It also offers sub-contracting and di …
  • Hoegh LNG Holdings Ltd (HLNG):企業の財務・戦略的SWOT分析
    Summary Hoegh LNG Holdings Ltd (Hoegh LNG), formerly known as Leif Hoegh & Co Ltd is an oil and gas company that offers floating energy solutions. The company's services include floating storage and regasification unit solutions, in-house ship management, floating LNG energy services, LNG regasifica …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆